ARCA biopharma (ABIO) was 12% higher after the data and safety monitoring committee recommended the completion of the ASPEN-COVID-19 phase 2b clinical trial with no alterations on the trial design.
|--BMO Capital Downgrades Life Storage to Market Perf...|
|Wedbush Lowers Block's Price Target to $100 From $14...|
|Advanced Drainage Systems Posts Higher Fiscal Q4 Pro...|
|Wedbush Cuts NVIDIA's Price Target to $190 From $300...|
|Eagle Materials Fiscal Q4 Earnings, Revenue Rise; Co...|